Paper Details

  1. Home
  2. Paper Details

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Author: , AppelS H, BergJ E, BradleyW G, BrooksB R, OlneyR K, PopeL E, SmithR A, ThistedR A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

AVP-923 (a combination of dextromethorphan hydrobromide and quinidine sulfate) is effective in treating pseudobulbar affect in ALS.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients with ALS commonly exhibit pseudobulbar affect. METHODS: The authors conducted a multicenter, randomized, double-blind, controlled, parallel, three-arm study to test a defined combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) (AVP-923) for the treatment...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/01.wnl.0000142042.50528.2f

データ提供：米国国立医学図書館（NLM）

Dextromethorphan/Quinidine for Pseudobulbar Affect in ALS: A Promising Treatment

[Amyotrophic lateral sclerosis (ALS)] is a devastating neurodegenerative disease that can significantly affect quality of life. This research explores the efficacy of [dextromethorphan/quinidine (AVP-923)] in treating [pseudobulbar affect (PBA)] in patients with ALS.

AVP-923: A Potential Solution for PBA in ALS

The study finds that [AVP-923 significantly improves PBA symptoms] in patients with ALS, leading to [decreased episodes of laughing and crying] and improved quality of life. This discovery offers hope for [managing PBA symptoms] and improving the well-being of individuals with ALS.

Addressing the Challenges of ALS

This study highlights the importance of [developing effective treatments] for PBA in ALS, a debilitating symptom that can significantly impact social interaction and quality of life. It underscores the need for [further research and clinical trials] to evaluate the long-term effects of AVP-923 and its potential benefits for ALS patients.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the vast and often unforgiving desert of ALS. AVP-923 could provide valuable relief for PBA symptoms, improving the quality of life for individuals living with this debilitating disease. Further research and clinical trials are crucial to ensure this treatment reaches those who need it most.

Date :
  1. Date Completed 2006-01-18
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15505150

DOI: Digital Object Identifier

10.1212/01.wnl.0000142042.50528.2f

Related Literature

Article Analysis
・Effects of dextromethorphan and quinidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.